Simplify Propel Opportunities ETF (SURI) Dividend Yield, History & Forecast

Simplify Propel Opportunities ETF (SURI) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. It pays a current dividend yield of 14.06% ($2.72 per share annually (TTM)). The most recent ex-dividend date was June 25, 2026, with payment scheduled for June 30, 2026. market capitalization is approximately $82M. Review SURI dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

SURI fund composition

SURI holds 19 positions, with 76.5% of assets in its ten largest. It charges an expense ratio of 2.82%, and manages $83.4M.

Top 10 holdings

HoldingWeight
PAGPPLAINS GP HLDGS L P40.75%
ACHVACHIEVE LIFE SCIENCES INC USD 0.00113.72%
MISTMILESTONE PHARMACEUTICALS INC NPV4.46%
DCTHDELCATH SYS INC USD 0.014.24%
CORTCORCEPT THERAPEUTICS INC USD 0.0012.93%
PHATPHATHOM PHARMACEUTICALS USD 0.00012.61%
COLLCOLLEGIUM PHARMACEUTICAL USD 0.0012.44%
ABEOABEONA THERAPEUTICS INC USD 0.011.86%
KYTXKYVERNA THERAPEUTICS IN USD 0.000011.78%
IVAINVENTIVA SA NPV ADR1.72%

Sector allocation

Healthcare53.9%Energy46.1%

Frequently Asked Questions about Simplify Propel Opportunities ETF (SURI)

What is Simplify Propel Opportunities ETF's dividend yield?
Simplify Propel Opportunities ETF (SURI) pays a current trailing twelve-month dividend yield of 14.06%, which works out to $2.72 per share annually based on the most recent payout schedule.
When does Simplify Propel Opportunities ETF pay distributions?
The most recent ex-dividend date was June 25, 2026. The next scheduled dividend payment date is June 30, 2026.
What does Simplify Propel Opportunities ETF invest in?
The Simplify Propel Opportunities ETF (SURI) aims to deliver substantial long-term capital growth. It achieves this by investing in companies across the biotechnology, pharmaceutical, healthcare technology, and life sciences industries. These particular firms are selected because they are believed to be overlooked by investors, suggesting significant potential for their value to increase. Propel, the fund's sub-advisor, applies its deep scientific and commercial knowledge in health sciences to identify and select the most promising investment opportunities within this sector.